| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Articles |
Division of Baxter Novum and Renal Medicine,1 Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; Division of Nephrology and Department of Internal Medicine,2 Kyungpook National University Hospital, Daegu, Korea
Correspondence to: B. Lindholm, Division of Baxter Novum and Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, K-56 Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden. bengt.lindholm{at}ki.se
Encapsulating peritoneal sclerosis (EPS) is rare but, with its high
morbidity and mortality, it represents one of the most serious complications
of long-term peritoneal dialysis. The pathogenesis of EPS has not been
elucidated yet; therefore, there has been a growing interest in establishing
appropriate animal models for EPS that would explain the pathogenesis of EPS
and verify the efficacy of therapeutic agents targeting pathways such as
angiogenesis and/or fibrosis. This brief review provides an update on
previously published animal experimental models of EPS. Based on this review,
we discuss some aspects of pathogenesis and treatment options in patients with
EPS. Experimental models of EPS cannot exactly reproduce human EPS because the
latter most likely has a diverse etiology, including the influences of uremia,
dialysis, and genetic factors. There is a need for new animal models that
would test interventions targeting multiple risk factors while also taking
into account putative genetic diversities that most likely are involved in
human EPS.
KEY WORDS: Encapsulating peritoneal sclerosis; animal model.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
